X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALEMBIC PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALEMBIC PHARMA SUN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 27.7 17.9 154.9% View Chart
P/BV x 2.9 4.5 64.3% View Chart
Dividend Yield % 0.4 0.7 57.8%  

Financials

 SUN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ALEMBIC PHARMA
Mar-18
SUN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs701645 108.6%   
Low Rs433470 92.2%   
Sales per share (Unadj.) Rs110.4166.1 66.5%  
Earnings per share (Unadj.) Rs11.021.9 50.1%  
Cash flow per share (Unadj.) Rs17.227.5 62.7%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.40.7 49.2%  
Book value per share (Unadj.) Rs158.8117.8 134.8%  
Shares outstanding (eoy) m2,399.26188.52 1,272.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.4 153.0%   
Avg P/E ratio x51.625.5 202.8%  
P/CF ratio (eoy) x32.920.3 162.3%  
Price / Book Value ratio x3.64.7 75.4%  
Dividend payout %18.218.3 99.7%   
Avg Mkt Cap Rs m1,360,021105,090 1,294.1%   
No. of employees `00017.8NA-   
Total wages/salary Rs m53,6716,228 861.7%   
Avg. sales/employee Rs Th14,890.9NM-  
Avg. wages/employee Rs Th3,017.1NM-  
Avg. net profit/employee Rs Th1,480.6NM-  
INCOME DATA
Net Sales Rs m264,89531,308 846.1%  
Other income Rs m8,38870 11,931.2%   
Total revenues Rs m273,28231,378 870.9%   
Gross profit Rs m56,0816,431 872.1%  
Depreciation Rs m14,9981,055 1,422.2%   
Interest Rs m5,17634 15,222.6%   
Profit before tax Rs m44,2955,413 818.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4521,204 702.3%   
Profit after tax Rs m26,3384,128 638.0%  
Gross profit margin %21.220.5 103.1%  
Effective tax rate %19.122.2 85.8%   
Net profit margin %9.913.2 75.4%  
BALANCE SHEET DATA
Current assets Rs m316,35918,247 1,733.7%   
Current liabilities Rs m198,64311,235 1,768.1%   
Net working cap to sales %44.422.4 198.4%  
Current ratio x1.61.6 98.1%  
Inventory Days Days9586 110.8%  
Debtors Days Days10861 175.5%  
Net fixed assets Rs m213,17820,035 1,064.0%   
Share capital Rs m2,399377 636.4%   
"Free" reserves Rs m378,60621,824 1,734.8%   
Net worth Rs m381,00622,201 1,716.1%   
Long term debt Rs m17,7215,000 354.4%   
Total assets Rs m643,02839,411 1,631.6%  
Interest coverage x9.6160.2 6.0%   
Debt to equity ratio x00.2 20.7%  
Sales to assets ratio x0.40.8 51.9%   
Return on assets %4.910.6 46.4%  
Return on equity %6.918.6 37.2%  
Return on capital %10.019.7 50.8%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m40,81614,722 277.3%   
Fx outflow Rs m30,1437,026 429.0%   
Net fx Rs m10,6737,696 138.7%   
CASH FLOW
From Operations Rs m39,0723,124 1,250.6%  
From Investments Rs m-33,708-8,844 381.1%  
From Financial Activity Rs m-15,3935,026 -306.2%  
Net Cashflow Rs m-7,359-693 1,061.5%  

Share Holding

Indian Promoters % 63.7 74.1 86.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 2.9 176.9%  
FIIs % 23.0 9.1 252.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 13.9 59.7%  
Shareholders   133,026 49,328 269.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PFIZER  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 18, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - LUPIN COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS